Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.75 |
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.75 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.75 |
| ▸ | HPGD | P15428 | 3/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.75 |
| ▸ | BLM | P54132 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | HTR2B | P41595 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.67 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.67 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefsumide SCHEMBL11217305 | 1.00 | HSD17B10 (0.75) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cefsumide SCHEMBL30688405 | 1.00 | HSD17B10 (0.75) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| SCHEMBL11652216 | 0.91 | ALDH1A1 (0.74) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| SCHEMBL11652221 | 0.91 | ALDH1A1 (0.74) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| SCHEMBL11655020 | 0.91 | ALDH1A1 (0.74) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| SCHEMBL612273 | 0.90 | MAPT (0.76) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| SCHEMBL11650995 | 0.89 | PTGS1 (0.59) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| SCHEMBL11650999 | 0.89 | PTGS1 (0.59) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| SCHEMBL11574032 | 0.89 | HSD17B10 (0.76) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| SCHEMBL11574041 | 0.89 | HSD17B10 (0.76) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 784 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12251417-B2 | Antimicrobial compounds from the genus Delftia | MINISTRY OF HEALTH, STATE OF ISRAEL (IL) | 2025-03-18 | — | — | US | claimed |
| US-20230398194-A1 | METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBIOTIC RESISTANCE | THERIVA BIOLOGICS INC (US) | 2023-12-14 | — | — | US | claimed |
| US-20220348645-A1 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-11-03 | — | — | US | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2021067628-A2 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| US-20200370098-A1 | Compositions and Methods for Identifying Secretory Antibody-Bound Microbes | HATTERAS VENTURE PARTNERS V, LP | 2020-11-26 | — | — | US | claimed |
| WO-2020223259-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | ILLUMINA, INC. (US) | 2020-11-05 | — | — | WO | claimed |
| WO-2020151669-A1 | BETA-LACTAM COMPOUNDS OR SALTS THEREOF FOR USE IN LONG-ACTING PREVENTION OR TREATMENT OF A GLUCOSE METABOLISM DISORDER | GLYCOLYSIS BIOMED CO., LTD (CN) | 2020-07-30 | — | — | WO | claimed |
| US-20200230149-A1 | BETA-LACTAM COMPOUNDS OR SALTS THEREOF FOR USE IN LONG-ACTING PREVENTION OR TREATMENT OF A GLUCOSE METABOLISM DISORDER | GLYCOLYSIS BIOMED CO., LTD. (TW) | 2020-07-23 | — | — | US | claimed |
| CN-109568323-A | Bactericidal composition and application thereof | 四环医药控股集团有限公司 | 2019-04-05 | — | — | CN | claimed |
| EP-2763540-A1 | COMPOSITIONS AND METHODS FOR ASSESSING AND TREATING INFLAMMATORY DISEASES AND DISORDERS | Yale University (US) | 2014-08-13 | — | — | EP | claimed |
| CN-103980480-A | Preparation and use of drug grafted polymer | YANG ZIJIAN | 2014-08-13 | — | — | CN | claimed |
| WO-2013163766-A1 | ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC | CANGENE CORPORATION (CA) | 2013-11-07 | — | — | WO | claimed |
| WO-2013067394-A1 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) AND INFECTIONS | Salix Pharmaceuticals, Ltd (US) | 2013-05-10 | — | — | WO | claimed |
| WO-2013036290-A1 | COMPOSITIONS AND METHODS FOR ASSESSING AND TREATING INFLAMMATORY DISEASES AND DISORDERS | YALE UNIVERSITY (US) | 2013-03-14 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2008005276-A2 | GROWTH FACTOR DELIVERY SYSTEM CONTAINING ANTIMICROBIAL AGENTS | DIRECTCONTACT LLC (US) | 2008-01-10 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12251417-B2 | Antimicrobial compounds from the genus Delftia | TUFM, DPM1, MGAM | HSD17B10 612/4885MAPT 2884/4885ALDH1A1 721/4885 |
| US-20200230149-A1 | BETA-LACTAM COMPOUNDS OR SALTS THEREOF FOR USE IN LONG-ACTING PREVENTION OR TREATMENT OF A GLUCOSE METABOLISM DISORDER | SLC5A1, SLC5A2, MGAM | HSD17B10 148/4885MAPT 1705/4885ALDH1A1 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.